Patients with bipolar I disorder experiencing acute manic or mixed episodes who completed either of two 3-week , double-blind trials with asenapine 5 or 10 mg twice daily , olanzapine 5 to 20 mg once daily , or placebo were eligible for this 9-week , double-blind extension study .
